Document:

Exhibit 10.1

 

AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT

 

AMENDMENT No. 3 dated as of
August 3, 2022 between Titan Pharmaceuticals, Inc. (the “Company”) and Marc Rubin
(“Executive”).

 

WHEREAS, the Company and Executive are parties
to an employment agreement dated April 2, 2019 (as amended in February 2021 and October 2021, the “Employment Agreement”);
and

 

WHEREAS, the Company and Executive wish to amend
the Employment Agreement in connection with a retention plan adopted by the compensation committee of the board of directors of the Company.

 

NOW, THEREFORE, for and in consideration of the
premises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows. Capitalized terms not defined
herein shall have the meanings set forth in the Employment Agreement.

 

		1.	Term. Section 1.2
of the Employment Agreement is hereby amended to read in its entirety as follows:

 

“1.2        Term. The term of this Agreement
shall begin on the Effective Date and shall continue until it is terminated pursuant to Section 4 herein (the “Term”).”

 

		2.	Definitions.

 

a.    Good
Reason. Section 4.6.3(iii) of the Employment Agreement is hereby amended to delete the proviso and read in its entirety
as follows:

 

“(iii) a material adverse
change in Executive’s duties, titles, authority, responsibilities or reporting relationships, with such determination being made
with reference to the greatest extent of your duties, titles, authority, responsibilities or reporting relationships, etc. as increased
(but not decreased) from time to time;”

 

b.    Change
of Control. Section 4.6.4 of the Employment Agreement is hereby amended by adding the following sentence:

 

“In addition, solely for the purpose
of the immediate acceleration of unvested options pursuant to Section 4.5 hereof, Change of Control shall also mean the election
to the board of directors of a slate nominated by any stockholder that is equal to or exceeds the number of directors constituting the
board immediately prior to such election.”

 

3.            Miscellaneous.
Except as expressly amended by this Amendment, the Employment Agreement remains in full force and effect.

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Amendment to be duly executed as of the day and year first above written.

 

	TITAN PHARMACEUTICALS, INC.	 
	 	 
	By:	 	 
	 	Name:	Kate Beebe DeVarney, Ph.D.	 
	 	Title:	President and Chief Operating Officer	 
	 	 
	EXECUTIVE	 
	 	 
	 	Name: Marc Rubin, M.D.Exhibit 10.2

 

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT

 

AMENDMENT No. 2
dated as of August 3, 2022 between Titan Pharmaceuticals, Inc. (the “Company”) and Katherine Beebe DeVarney
(“Executive”).

 

WHEREAS, the Company and Executive are parties
to an employment agreement dated November 1, 2018 (as amended in February 2021, the “Employment Agreement”); and

 

WHEREAS, the Company and Executive wish to amend
the Employment Agreement in connection with a retention plan adopted by the compensation committee of the board of directors of the Company.

 

NOW, THEREFORE, for and in consideration of the
premises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows. Capitalized terms not defined
herein shall have the meanings set forth in the Employment Agreement.

 

1.            Definitions.

 

a.     Cause.
Section 4.6.2 of the Employment Agreement is hereby amended to delete the words “Senior
Vice” in the last sentence.

 

b.     Good
Reason. Section 4.6.3(iii) of the Employment Agreement is hereby to amended to read in its entirety as follows:

 

“(iii) a material diminution
in Executive's duties, authority or responsibilities;”

 

c.     Change
of Control. Section 4.6.4 of the Employment Agreement is hereby amended by adding the following sentence:

 

“In addition, solely for the purpose
of the immediate acceleration of unvested options pursuant to Section 4.5 hereof, Change of Control shall also mean the election
to the board of directors of a slate nominated by any stockholder that is equal to or exceeds the number of directors constituting the
board immediately prior to such election.”

 

2.            Miscellaneous.
Except as expressly amended by this Amendment, the Employment Agreement remains in full force and effect.

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Amendment to be duly executed as of the day and year first above written.

 

	TITAN PHARMACEUTICALS, INC.	 
	 	 
	By:	 	 
	 	Name:	M. David MacFarlane, Ph.D.	 
	 	Title:	Chairman. Compensation Committee	 
	 	 
	EXECUTIVE	 
	 	 
	 	Name:	Kate Beebe DeVarney, Ph.D.Exhibit
10.1

 

fuboTV
INC.

 

SHARES
OF COMMON STOCK

(PAR VALUE $0.0001 PER SHARE)

 

SALES
AGREEMENT

 

August
4, 2022

 

Evercore
Group L.L.C.

55
East 52nd Street

New
York, NY 10055

 

Citigroup
Global Markets Inc.

388
Greenwich Street

New
York, New York 10013

 

Morgan
Stanley & Co. LLC

1585
Broadway

New
York, New York 10036

 

Needham
& Company, LLC

250
Park Avenue, 10th Floor

New
York, NY 10177

 

To
Whom It May Concern:

 

fuboTV
Inc., a Florida corporation (the “Company”), confirms its agreement (this “Agreement”)
with each of Evercore Group L.L.C., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Needham & Company, LLC (each
an “Agent”, and collectively, the “Agents”), as follows:

 

1.
Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject
to the conditions set forth herein, it may issue and sell through the Agents, shares of common stock having an aggregate gross sales
price of up to $350,000,000.00 (the “Placement Shares”) of the Company, par value $0.0001 per share (the “Common
Stock”); provided, however, that in no event shall the Company issue or sell through the Agents such number or dollar
amount of Placement Shares that would (a) exceed the number or dollar amount of shares of Common Stock registered on the effective Registration
Statement (as defined below) pursuant to which the offering is being made, (b) exceed the number of authorized but unissued shares of
Common Stock (less shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company
or otherwise reserved from the Company’s authorized capital stock), (c) exceed the number or dollar amount of shares of Common
Stock permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable) or (d) exceed the number or dollar
amount of shares of Common Stock for which the Company has filed a Prospectus Supplement (as defined below) (the lesser of (a), (b),
(c) and (d), the “Maximum Amount”). Notwithstanding anything to the contrary contained herein, the parties
hereto agree that compliance with the limitations set forth in this Section 1 on the amount of Placement Shares issued and sold under
this Agreement shall be the sole responsibility of the Company and that the Agents shall have no obligation in connection with such compliance.
The offer and sale of Placement Shares through the Agents will be effected pursuant to the Registration Statement filed by the Company
and which will be declared effective by the Securities and Exchange Commission (the “Commission”), although
nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement (as defined below) to issue Common
Stock.

 

    	 

     

    

 

The
Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended (the “Securities Act”),
and the rules and regulations thereunder (the “Securities Act Regulations”), with the Commission a registration
statement on Form S-3 (File No. 333-258428), including a base prospectus, relating to certain securities, including the Placement Shares
to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file
in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and the rules and regulations thereunder. The Company has prepared a prospectus or a prospectus supplement to the base prospectus included
as part of the registration statement, which prospectus or prospectus supplement relates to the Placement Shares to be issued from time
to time by the Company (the “Prospectus Supplement”). The Company will furnish to the Agents, for use by the
Agents, copies of the prospectus included as part of such registration statement, as supplemented, by the Prospectus Supplement, relating
to the Placement Shares to be issued from time to time by the Company. The Company may file one or more additional registration statements
from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable (which shall be
a Prospectus Supplement), with respect to the Placement Shares. Except where the context otherwise requires, such registration statement(s),
including all documents filed as part thereof or incorporated by reference or deemed incorporated by reference therein, and including
any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the
Securities Act Regulations or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act Regulations,
is herein called the “Registration Statement.” The base prospectus or base prospectuses, including all documents
incorporated therein by reference or deemed incorporated by reference therein, included in the Registration Statement, as it may be supplemented,
if necessary, by the Prospectus Supplement, in the form in which such prospectus or prospectuses and/or Prospectus Supplement have most
recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act Regulations, together with the
then issued Issuer Free Writing Prospectus(es), if any, (as defined below), is herein called, collectively, the “Prospectus.”

 

Any
reference herein to the Registration Statement, any Prospectus Supplement, Prospectus or any Issuer Free Writing Prospectus shall be
deemed to refer to and include the documents, if any, incorporated by reference and deemed to be incorporated by reference therein (the
“Incorporated Documents”), including, unless the context otherwise requires, the documents, if any, filed as
exhibits to such Incorporated Documents. Any reference herein to the terms “amend,” “amendment” or “supplement”
with respect to the Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall be
deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration
Statement, or the date of the Prospectus Supplement, Prospectus or such Issuer Free Writing Prospectus, as the case may be, and incorporated
therein by reference. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment
or supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering
Analysis and Retrieval system, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively,
“EDGAR”).

 

    	2

     

    

 

2.
Placements. Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a “Placement”),
it will notify the Designated Agent (as defined below) by email notice (or other method mutually agreed to by the parties) of the number
of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Placement
Shares that may be sold in any one day and any minimum price below which sales may not be made (a “Placement Notice”),
the form of which is attached hereto as Schedule 1. The Placement Notice shall originate from any of the individuals from the
Company set forth on Schedule 3 (with a copy to each of the other individuals from the Company listed on such schedule), and shall
be addressed to each of the individuals from the Designated Agent set forth on Schedule 3, as such Schedule 3 may be amended
from time to time. The Placement Notice shall be effective unless and until (a) the Designated Agent declines in writing, by any means
provided for under Section 13, to accept the terms contained therein for any reason, in its sole discretion, (b) the entire amount
of the Placement Shares thereunder have been sold, (c) the Company suspends or terminates the Placement Notice in its sole discretion,
(d) the Company issues a subsequent Placement Notice with parameters superseding those of the earlier dated Placement Notice, or (e)
this Agreement has been terminated under the provisions of Section 12. The amount of any discount, commission or other compensation
to be paid by the Company to the Designated Agent in connection with the sale of the Placement Shares shall be calculated in accordance
with the terms set forth in Schedule 2. It is expressly acknowledged and agreed that neither the Company nor the Designated Agent
will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement
Notice to the Designated Agent and the Designated Agent does not decline such Placement Notice pursuant to the terms set forth above,
and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms
of a Placement Notice, the terms of the Placement Notice will control. As used herein, “Designated Agent” shall
mean, with respect to any Placement Notice, the specific Agent selected by the Company to act as sales agent, provided that such Agent
selected by the Company has agreed to act as sales agent.

 

3.
Sale of Placement Shares by the Agents. Subject to the provisions of Section 5(a), the Designated Agent, for the period specified
in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices, to sell
the Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The Designated
Agent will provide written confirmation to the Company no later than the opening of the Trading Day (as defined below) immediately following
the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day,
the compensation payable by the Company to the Designated Agent pursuant to Section 2 with respect to such sales, and the Net
Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the Designated Agent (as set forth
in Section 5(b)) from the gross proceeds that it receives from such sales. Subject to the terms of the Placement Notice and the
terms of this Agreement, the Designated Agent may sell Placement Shares by any method permitted by law deemed to be an “at the
market offering” as defined in Rule 415(a)(4) of the Securities Act Regulations, including sales made directly on or through the
New York Stock Exchange (the “Exchange”) or any other existing trading market for the Common Stock or in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other
method permitted by law. “Trading Day” means any day on which Common Stock is traded on the Exchange.

 

4.
Suspension of Sales. The Company or the Designated Agent may, upon notice to the other party in writing (including by email correspondence
to each of the individuals of the other party set forth on Schedule 3, if receipt of such correspondence is actually acknowledged
by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable
facsimile transmission or email correspondence to each of the individuals of the other party set forth on Schedule 3), suspend
any sale of Placement Shares (a “Suspension”); provided, however, that such Suspension shall not affect
or impair any party’s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. While
a Suspension is in effect, any obligation under Sections 7(l), 7(m), and 7(n) with respect to the delivery of certificates,
opinions, or comfort letters to the Agents, shall be waived. Each of the parties agrees that no such notice under this Section 4 shall
be effective against any other party unless it is made to one of the individuals named on Schedule 3 hereto, as such Schedule
may be amended from time to time. Notwithstanding any other provision of this Agreement, during any period in which the Company is in
possession of material non-public information, the Company agrees that (a) no sale of Placement Shares will take place, (b) the Company
shall not request the sale of any Placement Shares, and (c) the Designated Agent shall not be obligated to sell or offer to sell any
Placement Shares.

 

    	3

     

    

 

5.
Sale and Delivery to the Agents; Settlement.

 

(a)
Sale of Placement Shares. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, upon the Designated Agent’s acceptance of the terms of a Placement Notice, and unless the sale of the Placement
Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, the Designated
Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading
and sales practices and applicable law and regulations, including applicable rules of the Exchange, to sell such Placement Shares up
to the amount specified, and otherwise in accordance with the terms of such Placement Notice. The Company acknowledges and agrees that
(i) there can be no assurance that the Designated Agent will be successful in selling Placement Shares, (ii) the Designated Agent will
incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other
than a failure by the Designated Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices
and applicable law and regulations, including applicable rules of the Exchange, to sell such Placement Shares as required under this
Agreement and (iii) the Designated Agent shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this
Agreement, except as otherwise agreed by the Designated Agent and the Company.

 

(b)
Settlement of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement
Shares will occur on the second (2nd) Trading Day (or such earlier day as is industry practice for regular-way trading) following the
date on which such sales are made (each, a “Settlement Date”). The Designated Agent shall notify the Company
of each sale of Placement Shares no later than the opening of the Trading Day immediately following the Trading Day on which it has made
sales of Placement Shares hereunder. The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the
Placement Shares sold (the “Net Proceeds”) will be equal to the aggregate sales price received by the Designated
Agent, after deduction for (i) the Designated Agent’s commission, discount or other compensation for such sales payable by the
Company pursuant to Section 2 hereof, and (ii) any transaction fees imposed by any Governmental Authority (as defined below) in
respect of such sales.

 

(c)
Delivery of Placement Shares. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically
transfer the Placement Shares being sold by crediting the Designated Agent’s or its designee’s account (provided the Designated
Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository
Trust Company through its Deposit and Withdrawal at Custodian system or by such other means of delivery as may be mutually agreed upon
by the parties hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each
Settlement Date, the Designated Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company
on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its
obligation to deliver Placement Shares on a Settlement Date through no fault of the Designated Agent, then the Company agrees that in
addition to and in no way limiting the rights and obligations set forth in Section 10(a) hereto, it will (i) hold the Designated
Agent harmless against any loss, claim, damage, or expense (including legal fees and expenses of its outside counsel), as incurred, arising
out of or in connection with such default by the Company or its transfer agent (if applicable) and (ii) pay to the Designated Agent any
commission or discount to which it would otherwise have been entitled absent such default.

 

    	4

     

    

 

(d)
Denominations; Registration. Certificates for the Placement Shares, if any, shall be in such denominations and registered in such
names as the Designated Agent may request in writing at least one full Business Day (as defined below) before the Settlement Date. The
certificates for the Placement Shares, if any, will be made available by the Company for examination and packaging by the Designated
Agent in The City of New York not later than noon (New York time) on the Business Day prior to the Settlement Date.

 

(e)
Limitations on Offering Size. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares
if, after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant to
this Agreement would exceed the lesser of (i) together with all sales of Placement Shares under this Agreement, the Maximum Amount and
(ii) the amount authorized from time to time to be issued and sold under this Agreement by the Company’s board of directors, a
duly authorized committee thereof or a duly authorized executive committee, and notified to the Designated Agent in writing. Under no
circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower
than the minimum price authorized from time to time by the Company’s board of directors, a duly authorized committee thereof or
a duly authorized executive committee, and notified to the Designated Agent in writing. Further, under no circumstances shall the Company
cause or permit the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.

 

6.
Representations and Warranties of the Company. The Company represents and warrants to, and agrees with the Agents that as of the
date of this Agreement and as of each Applicable Time (as defined below) unless such representation, warranty or agreement specifies
a different date or time:

 

(a)
Registration Statement and Prospectus. The Company and the transactions contemplated by this Agreement meet the requirements for
and comply with the applicable conditions set forth in Form S-3 (including General Instructions I.A and I.B) under the Securities Act.
The Registration Statement has been filed with the Commission and will be declared effective by the Commission under the Securities Act
prior to the issuance of any Placement Notices by the Company. The Prospectus Supplement will name the Agents as the agents in the section
entitled “Plan of Distribution.” The Company has not received, and has no notice or knowledge of, any order of the Commission
preventing or suspending the use of the Registration Statement, or threatening or instituting proceedings for that purpose or pursuant
to Section 8A under the Securities Act. The Registration Statement and the offer and sale of Placement Shares as contemplated hereby
meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said Rule. Any statutes, regulations,
contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits
to the Registration Statement have been so described or filed. Copies of the Registration Statement, the Prospectus, and any such amendments
or supplements and all documents incorporated by reference therein that were filed with the Commission on or prior to the date of this
Agreement have been delivered, or are available through EDGAR, to the Agents and their counsel. The Company has not distributed and,
prior to the later to occur of each Settlement Date and completion of the distribution of the Placement Shares, will not distribute any
offering material in connection with the offering or sale of the Placement Shares other than the Registration Statement and the Prospectus
and any Issuer Free Writing Prospectus (as defined below) to which the Agents have consented (which consent will not be unreasonably
conditioned, withheld or delayed). The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is currently listed
on the Exchange under the trading symbol “FUBO.” The Company has taken no action designed to, or likely to have the effect
of, terminating the registration of the Common Stock under the Exchange Act, delisting the Common Stock from the Exchange, nor has the
Company received any notification that the Commission or the Exchange is contemplating terminating such registration or listing. The
Prospectus delivered to the Agents for use in connection with the sale of the Placement Shares pursuant to this Agreement will be identical
to the versions of the Prospectus created to be transmitted to the Commission for filing via EDGAR, except to the extent permitted by
Regulation S-T. To the Company’s knowledge, it is in compliance with all applicable listing requirements of the Exchange.

 

    	5

     

    

 

(b)
Accurate Disclosure. Neither the Registration Statement nor any amendment thereto, at its effective time or at the Applicable
Time contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading. As of the date thereof and at each Applicable
Time, none of the Prospectus and any Issuer Free Writing Prospectus or any amendment or supplement thereto, included, includes or will
include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. The documents incorporated by reference
in the Prospectus or any Prospectus Supplement did not, and any further documents filed and incorporated by reference therein will not,
when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to be stated
in such document or necessary to make the statements in such document, in light of the circumstances under which they were made, not
misleading. The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration
Statement (or any amendment thereto), the Prospectus (or any amendment or supplement thereto) or any Issuer Free Writing Prospectus made
in reliance upon and in conformity with written information furnished to the Company by the Agents expressly for use therein. For purposes
of this Agreement, the only information so furnished are the statements set forth in the seventh paragraph and the first sentence of
the eighth paragraph under the caption “Plan of Distribution” in the Prospectus (collectively, the “Agent
Information”).

 

(c)
Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus, as of its issue date or as of each Applicable Time, conflicts
or will conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated document
deemed to be a part thereof that has not been superseded or modified.

 

(d)
Company Not Ineligible Issuer. The Company was not and is not an ineligible issuer as defined in Rule 405 under the Securities
Act at the times specified in Rules 164 and 433 under the Securities Act in connection with the offering of the Placement Shares.

 

(e)
This Agreement. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and binding
agreement of the Company enforceable in accordance with its terms, except to the extent that (i) enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general equitable principles
and (ii) the indemnification and contribution provisions of Section 10 hereof may be limited by federal and state securities laws
and public policy considerations in respect thereof.

 

(f)
Authorization of the Placement Shares. The Placement Shares, when issued and delivered pursuant to the terms approved by the board
of directors of the Company or a duly authorized committee thereof, or a duly authorized executive committee, against payment therefor
as provided herein, will be duly and validly authorized and issued and fully paid and non- assessable, and the issuance and sale of the
Placement Shares will not be subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase
the Placement Shares.

 

(g)
No Applicable Registration or Other Similar Rights. There are no persons with registration rights, preemptive rights, rights of
first refusal or other similar rights to purchase, subscribe for or have any equity or debt securities registered for sale under the
Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived or
satisfied.

 

    	6

     

    

 

(h)
No Material Adverse Change. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Prospectus or the Issuer Free Writing Prospectuses: (i) There has been no material adverse change, or any development that could
be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, operations,
operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of
the Company and its subsidiaries, considered as one entity, or in the ability of the Company to consummate the transactions contemplated
by this Agreement or perform its obligations hereunder (any such change being referred to herein as a “Material Adverse Change”);
(ii) other than as contemplated by this Agreement, the Company and its subsidiaries, considered as one entity, have not incurred any
material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with its business
from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor
dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its
subsidiaries, considered as one entity, and have not entered into any material transactions not in the ordinary course of business; and
(iii) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness
of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or,
except for dividends paid to the Company or other subsidiaries, by any of the Company’s subsidiaries on any class of capital stock,
or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.

 

(i)
Independent Accountants. Each of LJ Soldinger Associates, LLC and KPMG US LLP has expressed its opinion with respect to the financial
statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of or incorporated
by reference into the Registration Statement and the Prospectus, is (i) an independent registered public accounting firm with respect
to the Company as required by the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”),
(ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under
the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or
revoked and who has not requested such registration to be withdrawn.

 

(j)
Financial Statements. The financial statements filed with the Commission incorporated by reference in the Registration Statement
and the Prospectus present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries
as of the dates indicated and the results of their operations, changes in stockholders’ equity and cash flows for the periods specified.
Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States
applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. No other
financial statements are required to be included in the Registration Statement and the Prospectus. The interactive data in eXtensible
Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called
for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.
No other financial statements or supporting schedules are required to be included in the Registration Statement or the Prospectus. All
disclosures contained in the Registration Statement, any preliminary prospectus, the Prospectus and any free writing prospectus that
constitute non-GAAP financial measures (as defined by the rules and regulations under the Securities Act and the Exchange Act) comply
with Regulation G under the Exchange Act and Item 10 of Regulation S- K under the Securities Act, as applicable. To the Company’s
knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed
to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of,
or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration
Statement and the Prospectus.

 

    	7

     

    

 

(k)
Company’s Accounting System. The Company and each of its subsidiaries make and keep accurate books and records and maintain
a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability
for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the
recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect
to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the
Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance
with the Commission’s rules and guidelines applicable thereto.

 

(l)
Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. The Company has established
and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s
principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which
the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated by management of the Company for effectiveness
as of the end of the Company’s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions
for which they were established. Since the end of the Company’s most recent audited fiscal year, except as otherwise disclosed
in the Registration Statement and the Prospectus, there have been no material weaknesses in the Company’s internal control over
financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The
Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

(m)
Incorporation and Good Standing of the Company. The Company has been duly incorporated and is validly existing as a corporation
in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and
operate its properties and to conduct its business as described in the Registration Statement and the Prospectus and to enter into and
perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good
standing in the State of Florida and each other jurisdiction in which such qualification is required, whether by reason of the ownership
or leasing of property or the conduct of business, except where the failure to qualify or to be in good standing could not reasonably
be expected to result in a Material Adverse Change.

 

(n)
Subsidiaries. Each of the Company’s “subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under
the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership
or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization
and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described
in the Registration Statement and the Prospectus, except where the failure to be in good standing could not reasonably be expected to
result in a Material Adverse Change. Each of the Company’s subsidiaries is duly qualified as a foreign corporation, partnership
or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification
is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to qualify
or be in good standing could not reasonably be expected to result in a Material Adverse Change. All of the issued and outstanding capital
stock or other equity or ownership interests of each of the Company’s subsidiaries have been duly authorized and validly issued,
are fully paid and nonassessable; and all shares of outstanding capital stock or other equity or ownership interests of the Company’s
subsidiaries held by the Company, directly or through subsidiaries, are owned free and clear of any security interest, mortgage, pledge,
lien, encumbrance or adverse claim. None of the outstanding capital stock or equity interest in any subsidiary was issued in violation
of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents of each of the
subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization
and are in full force and effect. The only subsidiaries of the Company are (i) fuboTV Media Inc., a Delaware corporation, (ii) fubo Gaming
Inc., a Delaware corporation, (iii) Molotov SAS, a company organized under the laws of France, and (iv) certain other subsidiaries which,
considered in the aggregate as a single subsidiary, do not constitute a significant subsidiary (as such term is defined in Rule 1-02
of Regulation S-X).

 

    	8

     

    

 

(o)
Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as set
forth in the Registration Statement and the Prospectus (other than for subsequent issuances, if any, pursuant to employee benefit plans,
or upon the exercise of outstanding options or warrants, in each case as described in the Registration Statement and the Prospectus).
The Placement Shares and the Company’s capital stock conforms and conform in all material respects to the description thereof contained
in the Registration Statement and the Prospectus. All of the issued and outstanding capital stock of the Company has been duly authorized
and validly issued, is fully paid and nonassessable and has been issued in compliance with all federal and state securities laws. None
of the outstanding capital stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to
subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights
of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital
stock of the Company or any of its subsidiaries other than those described in the Registration Statement and the Prospectus. The descriptions
of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder,
set forth in the Registration Statement and the Prospectus accurately and fairly presents the information required to be shown with respect
to such plans, arrangements, options and rights.

 

(p)
Stock Exchange Listing. The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and are
listed on the Exchange and the Company has taken no action designed to, or likely to have the effect of, terminating the registration
of the Placement Shares under the Exchange Act or delisting the shares of Common Stock from the Exchange, nor has the Company received
any notification that the Commission or the Exchange is contemplating terminating such registration or listing. To the Company’s
knowledge, it is in compliance with all applicable listing requirements of the Exchange.

 

(q)
Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. Neither the Company nor any of its
subsidiaries is (i) in violation of its charter or by-laws, partnership agreement or operating agreement or similar organizational documents,
as applicable, or (ii) is in default (or, with the giving of notice or lapse of time, would be in default) (“Default”)
under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without
limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or
relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to
which any of their respective properties or assets are subject (each, an “Existing Instrument”), except in
the case of this clause (ii) for such Defaults as could not reasonably be expected, individually or in the aggregate, to result in a
Material Adverse Change. The Company’s execution, delivery and performance of this Agreement and consummation of the transactions
contemplated hereby and by the Registration Statement and the Prospectus and the issuance and sale of the Placement Shares (including
the use of proceeds from the sale of the Placement Shares as described in the Registration Statement and the Prospectus under the caption
“Use of Proceeds”) (i) have been duly authorized by all necessary corporate action and will not result in any violation of
the provisions of the charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable,
of the Company or any subsidiary (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event
(as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the
Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii) will
not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any
of its subsidiaries. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental
or regulatory authority or agency, is required for the Company’s execution, delivery and performance of this Agreement and consummation
of the transactions contemplated hereby and by the Registration Statement and the Prospectus, except such as have been obtained or made
by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities
or blue sky laws or the Financial Industry Regulatory Authority, Inc. (“FINRA”). As used herein, a “Debt
Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time would
give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right
to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.

 

    	9

     

    

 

(r)
Necessary Agreements. Neither the Company, nor any of its subsidiaries, is in material default or material breach under the terms
of any agreement necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted
(“Necessary Agreements”), nor, to the Company’s knowledge, does any condition exist that, with notice
or lapse of time or both, would constitute a material default or material breach thereunder by the Company except, in each case, as otherwise
disclosed in the Registration Statement or Prospectus. The Company has not received any notice of termination or cancellation under any
Necessary Agreement, received any notice of breach or default in any material respect under any Necessary Agreement or granted to any
third party any rights, adverse or otherwise, that would constitute a breach of any Necessary Agreement except, in each case, as otherwise
disclosed in the Registration Statement.

 

(s)
Compliance with Laws. The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations,
except where failure to be so in compliance could not reasonably be expected, individually or in the aggregate, to result in a Material
Adverse Change.

 

(t)
No Material Actions or Proceedings. Except as disclosed in the Prospectus and Registration Statement, there is no action,
suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of
the Company, threatened, against or affecting the Company or any of its subsidiaries, which could reasonably be expected, individually
or in the aggregate, to result in a Material Adverse Change. Except as would not reasonably be expected, individually or in the aggregate,
to result in a Material Adverse Change, (i) no labor dispute with the employees of the Company or any of its subsidiaries, or with the
employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, (ii) to the knowledge of the Company,
is threatened or imminent.

 

    	10

     

    

 

(u)
Intellectual Property Rights. The Company and its subsidiaries own, or have obtained valid and enforceable licenses for the inventions,
technology, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets, and other intellectual property
described in the Registration Statement or the Prospectus as being owned or licensed by them or which are necessary for the conduct of
their respective businesses as currently conducted or as currently proposed to be conducted (collectively, “Intellectual
Property”), and except  as would not reasonably be expected, individually or in the aggregate, to result in a Material
Adverse Change, the conduct of their respective businesses does not and will not infringe, misappropriate or otherwise conflict with
any such rights of others. The Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be
invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such
adjudication. To the Company’s knowledge, there are no third parties who have rights to any Intellectual Property, including no
liens, security interests, or other encumbrances, except as otherwise disclosed in the Registration Statement and the Prospectus, and,
to the Company’s knowledge, there is no infringement by third parties of any Intellectual Property. Except as otherwise disclosed
in the Registration Statement and the Prospectus, there is no pending or, to the Company’s knowledge, threatened, action, suit,
proceeding or claim by others: (i) challenging the Company’s rights in or to any Intellectual Property, and the Company is unaware
of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (ii) challenging the validity, enforceability
or scope of any Intellectual Property and the Company is unaware of any facts which would form a reasonable basis for any such action,
suit, proceeding or claim; or (iii) asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would,
upon the commercialization of any product or service described in the Registration Statement and the Prospectus as under development,
infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others,
and each of the Company and its subsidiaries is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding
or claim. The Company and its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which
Intellectual Property has been licensed to the Company or any of its subsidiaries, and all such agreements are in full force and effect.
To the Company’s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual
Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property,
including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments
with their employees and independent contractors, and to the Company’s knowledge, no employee or independent contractor of the
Company is in or has been in violation of any term of any employment or independent contractor agreement, patent disclosure agreement,
invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant
to or with a former employer or counterparty where the basis of such violation relates to such employee’s employment, or such independent
contractor’s engagement, with the Company. The duty of candor and good faith as required by the United States Patent and Trademark
Office during the prosecution of the United States patents and patent applications included in the Intellectual Property have been complied
with; and in all foreign offices having similar requirements, all such requirements have been complied with. None of the Intellectual
Property or technology (including information technology and outsourced arrangements) employed by the Company or its subsidiaries has
been obtained or is being used by the Company or its subsidiaries in violation of any contractual obligation binding on the Company or
its subsidiaries or any of their respective officers, directors or employees or otherwise in violation of the rights of any persons,
including with respect to software or other materials distributed under an “open source” or similar licensing model that
meets the definition of “open source” promulgated by the Open Source Initiative located online at http://opensource.org/osd
(e.g., GNU General Public License, GNU Lesser General Public License, and GNU Affero General Public License).

 

(v)
All Necessary Permits, etc. The Company and its subsidiaries possess such valid and current licenses, certificates, authorizations,
approvals, consents or permits required by state, federal or foreign regulatory agencies or bodies, including, without limitation, any
permits required by the Federal Communications Commission, to conduct their respective businesses as currently conducted and as described
in the Registration Statement and the Prospectus (“Permits”). Neither the Company, nor any of its subsidiaries
is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to the revocation or suspension
of, or non-compliance with, any such certificate, authorization or permit. The Company and its subsidiaries have filed, obtained, maintained
or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required
by any Permits and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
were timely, complete, correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission), except,
in each case, where the failure to do so would not reasonably be expected, individually or in the aggregate, to result in a Material
Adverse Change.

 

    	11

     

    

 

(w)
Privacy. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and
federal data privacy and security laws and regulations, including without limitation HIPAA, CCPA, and the European Union General Data
Protection Regulation (“GDPR”) (EU 2016/679) (collectively, the “Privacy Laws”).
To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps to
ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection,
storage, use, processing, disclosure, handling, and analysis of Personal Data and Confidential Data (the “Policies”).
The Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory
rules or requirements, and none of such disclosures made or contained in any Policy have been inaccurate or in violation of any applicable
laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary:
(i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy
Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently
conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law;
or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.

 

(x)
Title to Properties. The Company and its subsidiaries have good and marketable title to all of the real and personal property
and other assets reflected as owned in the financial statements referred to in this Agreement or elsewhere in the Registration Statement
or the Prospectus, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and
other defects. The real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries
are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made
or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary.

 

(y)
Tax Law Compliance. Except as disclosed in the Registration Statement and the Prospectus, the Company and its subsidiaries have
timely filed all necessary federal, state and foreign income and other material tax returns or have properly requested extensions thereof,
and have paid all taxes required to be paid by any of them (whether or not reflected on any tax return) and, if due and payable, any
related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate
proceedings, to the extent that failure to file or pay could reasonably be expected to result in a Material Adverse Change. The Company
has made adequate charges, accruals and reserves in the Company’s applicable financial statements in respect of all federal, state
and foreign income and other material taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has
not been finally determined, to the extent that the failure to do so could reasonably be expected to result in a Material Adverse Change.
Except as disclosed in the Registration Statement and the Prospectus, no tax deficiency has been determined adversely to the Company
or its subsidiaries which could reasonably be expected to result in a Material Adverse Change.

 

(z)
Insurance. Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable institutions with
policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses
including, but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against
theft, damage, destruction, acts of vandalism and earthquakes. Except as otherwise disclosed in the Registration Statement and Prospectus,
the Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew its existing insurance coverage
as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to
conduct its business as now conducted and at a cost that could not be expected to have a Material Adverse Change. Neither the Company
nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied, the denial of which
could reasonably be expected to result in a Material Adverse Change.

 

    	12

     

    

 

(aa)
Compliance with Environmental Laws. Except as could not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Change: (i) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute,
law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including
any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment
(including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without
limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic
substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
“Environmental Laws”); (ii) the Company and its subsidiaries have all permits, authorizations and approvals
required under any applicable Environmental Laws and are each in compliance with their requirements; (iii) there are no pending or, to
the Company’s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens,
notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its
subsidiaries; and (iv) to the Company’s knowledge, there are no events or circumstances that might reasonably be expected to form
the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency,
against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.

 

(bb)
ERISA Compliance. The Company and its subsidiaries and any “employee benefit plan” (as defined under the Employee
Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”))
established or maintained by the Company, its subsidiaries or their “ERISA Affiliates” (as defined below) are in compliance
in all material respects with ERISA. “ERISA Affiliate” means, with respect to the Company or any of its subsidiaries, any
member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended,
and the regulations and published interpretations thereunder (the “Code”) of which the Company or such subsidiary
is a member. No “reportable event” (as defined under ERISA) has occurred or is reasonably expected to occur with respect
to any “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates.
No “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if
such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined
under ERISA) that could reasonably be expected to result in a Material Adverse Change. Neither the Company, its subsidiaries nor any
of their ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect
to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the Code.
Each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended
to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which
would reasonably be expected to cause the loss of such qualification.

 

(cc)
Company Not an “Investment Company.” The Company is not, and immediately after the receipt of payment for the
Placement Shares and the application of the proceeds therefrom as described under the caption “Use of Proceeds” in the Registration
Statement or the Prospectus, will not be, required to be registered as an “investment company” under the Investment Company
Act of 1940, as amended (the “Investment Company Act”).

 

    	13

     

    

 

(dd)
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken,
directly or indirectly, any action designed to or that would be expected to cause or result in stabilization or manipulation of the price
of the capital stock of the Company or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange
Act (“Regulation M”)) with respect to the capital stock of the Company, whether to facilitate the sale or resale
of the Placement Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M.

 

(ee)
Related-Party Transactions. There are no business relationships or related-party transactions involving the Company or any of
its subsidiaries or any other person required to be described in the Registration Statement or the Prospectus that have not been described
as required.

 

(ff)
FINRA Matters. All of the information provided to the Agents or their counsel for the Agents by the Company, its counsel, its
officers and directors and, to the Company’s knowledge, the holders of any securities (debt or equity) or options to acquire any
securities of the Company in connection with the offering of the Placement Shares is true, complete and correct in all material respects
and compliant with FINRA’s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA
Rules or NASD Conduct Rules is true, complete and correct in all material respects. The Company meets the definition of the term “experienced
issuer” specified in FINRA Rule 5110(j)(6).

 

(gg)
Statistical and Market-Related Data. All statistical, demographic and market-related data included in the Registration Statement
or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate.
To the extent required, the Company has obtained the written consent to the use of such data from such sources.

 

(hh)
Anti-Bribery. (i) None of the Company or its subsidiaries or controlled affiliates, or any director, officer, or employee
thereof, or to the knowledge of the Company, any agent or representative of the Company or of any of its subsidiaries or controlled
affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of
the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official
(including any officer or employee of a government or government-owned or controlled entity or of a public international organization,
or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office) in order to improperly influence official action, or to any person in each case in violation of any applicable
anti-corruption laws; (ii) the Company and its subsidiaries and controlled affiliates have conducted their businesses in compliance
with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably
designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; and (iii) neither
the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment,
promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable
anti-corruption laws.

 

(ii)
Money Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III
of Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, the Currency
and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules
and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by
any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or
before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect
to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

    	14

     

    

 

(jj)
OFAC. Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company,
after due inquiry, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject
or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”)
or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury of the United
Kingdom, or other relevant sanctions authority (collectively, “Sanctions”); nor is the Company or any of its
subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without
limitation, the Crimea region of Ukraine, the so-called Donetsk People’s Republic and the so-called Luhansk People’s Republic
or any other “Covered Region of Ukraine” identified pursuant to Executive Order 14065, Cuba, Iran, North Korea, and Syria
(each a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of this offering,
or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity,
for the purpose of financing, funding or facilitating the activities of or business with or of any person, or in any country or territory,
that at the time of such financing, funding or facilitation, is the subject or the target of Sanctions or in any other manner that will
result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor
or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are
not now knowingly engaged in, and will not engage in, any dealings or transactions with any person, or in any country or territory, that
at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.

 

(kk)
Brokers. Except pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company
any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

 

(ll)
Forward-Looking Statements. Each financial or operational projection or other “forward-looking statement” (as defined
by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement or the Prospectus (i)
was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions,
estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those
factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made
with the knowledge of an executive officer or director of the Company that was false or misleading.

 

(mm)
No Outstanding Loans or Other Extensions of Credit. The Company does not have any outstanding extension of credit, in the form
of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of
credit as are expressly permitted by Section 13(k) of the Exchange Act.

 

(nn)
No Contract Terminations. Neither the Company nor any of its subsidiaries has sent or received any communication regarding termination
of, or intent not to renew, any of the contracts or agreements referred to or described in the Registration Statement and the Prospectus,
and no such termination or non-renewal has been threatened by the Company or any of its subsidiaries or, to the Company’s knowledge,
any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.

 

    	15

     

    

 

(oo)
Dividend Restrictions. No subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends
to the Company, or from making any other distribution with respect to such subsidiary’s equity securities or from repaying to the
Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such
subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary.

 

(pp)
Required Filings. The Company has timely made all filings required to be made by it under the Exchange Act.

 

(qq)
Cybersecurity; Data Protection. The Company and its subsidiaries’ information technology assets and equipment, computers,
systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are
adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company
and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and
administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the
integrity, continuous operation, redundancy and security of all IT Systems and data, including all Personal Data (defined below) and
all sensitive, confidential or regulated data (“Confidential Data”) used in connection with their businesses.
“Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address,
photograph, social security number or tax identification number, driver’s license number, passport number, credit card number,
bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information”
under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by GDPR (as defined below); (iv) any
information which would qualify as “protected health information” under the Health Insurance Portability and Accountability
Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”);
(v) any “personal information” as defined by the California Consumer Privacy Act (“CCPA”); and
(vi) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any data related to an identified person’s health or sexual orientation. There have been no breaches, violations,
outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the
duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its
subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations
of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems, Confidential Data, and Personal Data and to the protection of such IT Systems, Confidential Data, and Personal
Data from unauthorized use, access, misappropriation or modification.

 

(rr)
Market Capitalization. At the time the Registration Statement was or will be originally declared effective, and at the time the
Company’s most recent Annual Report on Form 10-K was filed with the Commission, the Company met or will meet the then applicable
requirements for the use of Form S-3 under the Securities Act, including, but not limited to, General Instruction I.B.1 of Form S-3.
The aggregate market value of the outstanding voting and non-voting common equity (as defined in Securities Act Rule 405) of the Company
held by persons other than affiliates of the Company (pursuant to Securities Act Rule 144, those that directly, or indirectly through
one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate
Shares”), was equal to or greater than $75.0 million (calculated by multiplying (x) the highest price at which the common
equity of the Company closed on the Exchange within 60 days of the date of this Agreement times (y) the number of Non-Affiliate Shares).
The Company is not a shell company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12
calendar months previously and if it has been a shell company at any time previously, has filed current Form 10 information (as defined
in Instruction I.B.6 of Form S-3) with the Commission at least 12 calendar months previously reflecting its status as an entity that
is not a shell company.

 

    	16

     

    

 

(ss)
Lending Relationship. Except as disclosed in the Registration Statement and the Prospectus, the Company does not intend to use
any of the proceeds from the sale of the Placement Shares to repay any outstanding debt owed to any affiliate of any Agent.

 

(tt)
No Rated Securities. Neither the Company nor its subsidiaries have any debt securities or preferred stock that are rated by any
“nationally recognized statistical rating agency” (as defined in Section 3(a)(62) of the Exchange Act).

 

(uu)
ATM Agreements. The Company is not a party to any agreement with an agent or underwriter for any other “at the market”
or continuous equity transaction.

 

(vv)
Agent Purchases. The Company acknowledges and agrees that the Agents have informed the Company that the Agents may, to the extent
permitted under the Securities Act and the Exchange Act, purchase and sell Common Stock for its own account while this Agreement is in
effect, provided, that (i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent that
an Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a “riskless principal”
or in a similar capacity) and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or sales by
the Agents.

 

(ww)
Margin Rules. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the
Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of
the Federal Reserve System or any other regulation of such Board of Governors.

 

(xx)
Transfer Taxes. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to be
paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid or
provided for by the Company and all laws imposing such taxes will be or will have been fully complied with.

 

(yy)
Officer’s Certificates. Any certificate signed by any officer of the Company or any of its subsidiaries delivered to the
Agents or their counsel for the Agents shall be deemed a representation and warranty by the Company (and not by such officer in his or
her personal capacity) to the Agents as to the matters covered thereby.

 

    	17

     

    

 

7.
Covenants of the Company. The Company covenants and agrees with the Agents that:

 

(a)
Registration Statement Amendments. After the date of this Agreement and during any period in which a Prospectus relating to any
Placement Shares is required to be delivered by any Agent under the Securities Act (including in circumstances where such requirement
may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), (i) the Company will notify the Agents promptly of the
time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference, has been filed with
the Commission and/or has become effective or any subsequent supplement to the Prospectus, other than documents incorporated by reference,
has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for
additional information, (ii) the Company will prepare and file with the Commission, promptly upon any Agent’s reasonable request,
any amendments or supplements to the Registration Statement or Prospectus that, in such Agent’s reasonable opinion, based on advice
of counsel, may be necessary or advisable in connection with the distribution of the Placement Shares by an Agent (provided, however,
that the failure of any Agent to make such request shall not relieve the Company of any obligation or liability hereunder, or affect
such Agent’s right to rely on the representations and warranties made by the Company in this Agreement and provided, further,
that the only remedy any Agent shall have with respect to the failure to make such filing shall be to cease making sales under this Agreement
until such amendment or supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration Statement
or Prospectus, other than documents incorporated by reference, relating to the Placement Shares or a security convertible into the Placement
Shares unless a copy thereof has been submitted to the applicable Agent within a reasonable period of time before the filing and such
Agent has not reasonably objected thereto within two business days following receipt thereof (provided, however, that (A) the
failure of the Agents to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agents’
right to rely on the representations and warranties made by the Company in this Agreement, (B) the Company has no obligation to provide
the Agents any advance copy of such filing or to provide the Agents an opportunity to object to such filing if the filing does not name
the Agents or does not relate to the transaction(s) herein described, and (C) the only remedy the Agents shall have with respect to the
failure by the Company to provide the Agents with such copy or the filing of such amendment or supplement despite the Agents’ objection
shall be to cease making sales under this Agreement) and the Company will furnish to the Agents at the time of filing thereof a copy
of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except for
those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement to the Prospectus, other than documents
incorporated by reference, to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities
Act or, in the case of any document to be incorporated therein by reference, to be filed with the Commission as required pursuant to
the Exchange Act, within the time period prescribed (the determination to file or not file any amendment or supplement with the Commission
under this Section 7(a), shall be based on the Company’s reasonable opinion or reasonable objections, and shall be made exclusively
by the Company).

 

(b)
Notice of Commission Stop Orders. The Company will advise the Agents, promptly after it receives notice or obtains knowledge thereof,
of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement,
of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceeding for any such purpose or pursuant to Section 8A under the Securities Act; and it will promptly use its commercially
reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company
will advise the Agents promptly after it receives any request by the Commission for any amendments to the Registration Statement or any
amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the Registration
Statement, the Prospectus or any Issuer Free Writing Prospectus, in each case, related to the offering of the Placement Shares.

 

    	18

     

    

 

(c)
Delivery of Prospectus; Subsequent Changes. During any period in which a Prospectus relating to the Placement Shares is required
to be delivered by any Agent under the Securities Act with respect to the offer and sale of the Placement Shares, (including in circumstances
where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), the Company will comply in all
material respects with all requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before
their respective due dates (taking into account any extensions available under the Exchange Act) all reports and any definitive proxy
or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any
other provision of or under the Exchange Act. If the Company has omitted any information from the Registration Statement pursuant to
Rule 430B under the Securities Act, it will use its reasonable best efforts to comply in all material respects with the provisions of
and make all requisite filings with the Commission pursuant to said Rule 430B and to notify the Agents promptly of all such filings.
If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then
existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to
comply with the Securities Act, the Company will promptly notify the Agents to suspend the offering of Placement Shares during such period
and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct
such statement or omission or effect such compliance; provided, however, that the Company may delay any such amendment or supplement
if, in the reasonable judgment of the Company, it is in the best interests of the Company to do so.

 

(d)
Listing of Placement Shares. Prior to the date of the first Placement Notice, the Company will use its commercially reasonable
efforts to cause the Placement Shares to be listed on the Exchange and to maintain such listing.

 

(e)
Delivery of Registration Statement and Prospectus. The Company will furnish to the Agents and their counsel (at the expense of
the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all
amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during any period in which
a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all Incorporated Documents),
in each case as soon as reasonably practicable and in such quantities as the Agents may from time to time reasonably request and, at
any Agent’s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares
may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus) to
the Agents to the extent such document is available on EDGAR.

 

(f)
Earnings Statement. To the extent not available on the Commission’s EDGAR filing system, the Company will make generally
available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company’s
current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of Section 11(a) and Rule 158
of the Securities Act.

 

(g)
Use of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”

 

(h)
Notice of Other Sales. During the pendency of any Placement Notice given hereunder, and for five (5) Trading Days following the
termination of any Placement Notice given hereunder, the Company shall provide the Agents notice as promptly as reasonably possible before
it offers to sell, contracts to sell, sells, grants any option to sell or otherwise disposes of any shares of Common Stock (other than
Placement Shares offered pursuant to the provisions of this Agreement) or securities convertible into or exchangeable for Common Stock,
warrants or any rights to purchase or acquire Common Stock; provided, that such notice or restrictions will not be applicable in connection
with the (i) issuance, grant or sale of Common Stock, options to purchase shares of Common Stock, restricted stock units or any other
equity awards, or Common Stock issuable upon the exercise of options, restricted stock units or other equity awards pursuant to any stock
option, stock bonus, employee stock purchase or other stock plan or arrangement described in the Prospectus, (ii) the issuance, grant
or sale of Common Stock, or securities convertible into or exercisable for Common Stock, which are not issued primarily for capital raising
purposes, in connection with any joint venture, commercial, strategic or collaborative relationship, or the acquisition or license by
the Company of the securities, businesses, property or other assets of another person or entity, (iii) the issuance or sale of Common
Stock pursuant to any dividend reinvestment plan that the Company may adopt from time to time provided the implementation of such is
disclosed to the Agents in advance or (iv) any shares of Common Stock issuable upon the exchange, conversion or redemption of securities
or the exercise or vesting of warrants, options or other rights in effect or outstanding. Notwithstanding the foregoing provisions, nothing
herein shall be construed to restrict the Company’s ability, or require the Company to provide notice to the Agents, to file a
registration statement under the Securities Act, including another prospectus supplement in connection with the Registration Statement
for the issuance and sale of shares other than the Placement Shares. The Company shall not directly or indirectly in any other “at
the market” or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose
of any Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable
for Common Stock, warrants or any rights to purchase or acquire, Common Stock prior to the later of the termination of this Agreement
and the thirtieth (30th) day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement
Notice.

 

    	19

     

    

 

(i)
Change of Circumstances. The Company will, at any time during a fiscal quarter in which the Company intends to tender a Placement
Notice or sell Placement Shares, advise the Agents promptly after it shall have received notice or obtained knowledge thereof, of any
information or fact that would alter or affect in any material respect any opinion, certificate, letter or other document required to
be provided to the Agents pursuant to this Agreement.

 

(j)
Due Diligence Cooperation. The Company will cooperate with any reasonable due diligence review conducted by the Agents or their
representatives in connection with the transactions contemplated hereby, including, without limitation, providing information and making
available documents and senior corporate officers, during regular business hours and at the Company’s principal offices, as the
Agents may reasonably request.

 

(k)
Required Filings Relating to Placement of Placement Shares. The Company agrees that on such dates as the Securities Act shall
require, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the
Securities Act, which prospectus supplement will set forth, to the extent required, within the relevant period, the amount of Placement
Shares sold through the Agents, the Net Proceeds to the Company and the compensation payable by the Company to the Agents with respect
to such Placement Shares (provided that the Company may satisfy its obligations under this Section 7(k)(i) by effecting a filing in accordance
with the Exchange Act with respect to such information), and (ii) deliver such number of copies of each such prospectus supplement to
each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market.

 

(l)
Representation Dates; Certificate. (1) Prior to the date of the first Placement Notice and (2) each time during the term of this
Agreement that a Placement Notice is outstanding the Company:

 

(i)
files the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to
an offering of securities other than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement Shares
by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration
Statement or the Prospectus relating to the Placement Shares;

 

(ii)
files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A that contains restated financial statements);

 

(iii)
files its quarterly reports on Form 10-Q under the Exchange Act; or

 

(iv)
files a current report on Form 8-K containing amended financial information (other than information “furnished” pursuant
to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of certain
properties as discontinued operations in accordance with Statement of Financial Accounting Standards No.144) under the Exchange Act (each
date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “Representation Date”);

 

    	20

     

    

 

the
Company shall furnish the Agents (but in the case of clause (iv) above only if the Agents reasonably determines that the information
contained in such Form 8-K is material) with a certificate in the form attached hereto as Schedule 7(l), modified, as necessary,
to relate to the Registration Statement and the Prospectus as amended or supplemented. The requirement to provide a certificate under
this Section 7(l) shall be waived without any action on the part of the Agents or the Company for any Representation Date occurring at
a time a Suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions
for the sale of Placement Shares hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring
Representation Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation
Date when a Suspension was in effect and did not provide the Agents with a certificate under this Section 7(l), then before the Company
delivers the instructions for the sale of Placement Shares or the Agents sell any Placement Shares pursuant to such instructions, the
Company shall provide the Agents with a certificate in the form attached hereto as Schedule 7(l) dated as of the date that the
instructions for the sale of Placement Shares are issued.

 

The first filing of a quarterly
report on Form 10-Q under the Exchange Act following the date of this Agreement shall constitute a Representation Date and the Company
shall deliver or cause to be delivered all required deliverables as would be required were a Placement Notice outstanding.

 

(m)
Legal Opinions. (i) On or prior to delivery of the first Placement Notice hereunder, the Company shall cause to be furnished to
the Agents (A) the written opinion and negative assurance letter of Latham & Watkins LLP (“L&W”)
and (B) the written opinion of Holland & Knight LLP (“H&K”), outside Florida counsel for the
Company, each in form and substance reasonably satisfactory to the Agents and their counsel, dated the date that such opinions and negative
assurance letter are required to be delivered, (ii) on or prior to delivery of the first Placement Notice hereunder, Fenwick &
West LLP (“F&W”), counsel to the Agents, shall furnish to the Agents a written opinion and negative assurance
letter, dated as of such date in form and substance reasonably satisfactory to the Agents, and (iii) on or prior to each Representation
Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto as Schedule 7(l), (A)
the Company shall cause to be furnished to the Agents the written opinion and negative assurance letter of L&W and
the written opinion of H&K, in form and substance reasonably satisfactory to the Agents and their counsel and (B) F&W
shall furnish to the Agents a written opinion and negative assurance letter, in form and substance reasonably satisfactory to the Agents,
each dated the date that the opinions and negative assurance letters are required to be delivered, respectively, modified, as necessary,
to relate to the Registration Statement and the Prospectus as then amended or supplemented at such Representation Date.

 

(n)
Comfort Letters. (i) On or prior to delivery of the first Placement Notice hereunder, the Company shall cause to be furnished
to the Agents letters from each of (A) KPMG US LLP and (B) LJ Soldinger Associates, LLC, the Company’s independent registered public
accounting firms (each, a “Comfort Letter”), dated the date that the Comfort Letters are delivered, in form
and substance satisfactory to the Agents, (1) separately confirming that such firm is an independent registered public accounting firm
within the meaning of the Securities Act and the PCAOB, (2) stating, as of such date, the conclusions and findings of such firm with
respect to the financial information and other matters ordinarily covered by accountants’ “comfort letters” to the
Agents in connection with registered public offerings (the first such letter, the “Initial Comfort Letter”),
and (ii) on or prior to each subsequent Representation Date with respect to which the Company is obligated to deliver a certificate in
the form attached hereto as Schedule 7(l), the Company shall cause each independent registered public accounting firm, as applicable,
to furnish the Agents a Comfort Letter in form and substance satisfactory to the Agents, dated the date that the Comfort Letters are
delivered, updating the Initial Comfort Letters with any information that would have been included in the Initial Comfort Letters had
they been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented
to the date of such letter.

 

    	21

     

    

 

(o)
Market Activities. The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes
or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Placement Shares or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M, or pay anyone
any compensation for soliciting purchases of the Placement Shares other than the Agents.

 

(p)
Investment Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that it will not be or
become, at any time prior to the termination of this Agreement, required to be registered as an “investment company,” as
such term is defined in the Investment Company Act.

 

(q)
No Offer to Sell. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agents in their capacity
as agents hereunder (such approval by the Agents not to be unreasonably conditioned, delayed or withheld), neither the Agents nor the
Company (including their agents and representatives, other than the Agents in their capacity as such) will make, use, prepare, authorize,
approve or refer to any written communication (as defined in Rule 405 under the Securities Act), required to be filed with the Commission,
that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.

 

(r)
Blue Sky and Other Qualifications. The Company will use its commercially reasonable efforts, in cooperation with the Agents, to
qualify the Placement Shares for offer and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under the
applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agents may designate and to maintain such
qualifications and exemptions in effect for so long as required for the offer and sale of the Placement Shares (but in no event for less
than one year from the date of this Agreement); provided, however, that the Company shall not be obligated to file any general
consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is
not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.
In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company will use its commercially reasonable
efforts to file such statements and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption,
as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one
year from the date of this Agreement).

 

(s)
Sarbanes-Oxley Act. The Company and the subsidiaries will maintain and keep accurate books and records reflecting their assets
and maintain internal accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with GAAP and including those policies and
procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and
dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the
preparation of the Company’s consolidated financial statements in accordance with GAAP, (iii) that receipts and expenditures of
the Company are being made only in accordance with management’s and the Company’s directors’ authorization, and (iv)
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s
assets that could have a material effect on its financial statements. Unless granted a waiver, the Company and the subsidiaries will
maintain such controls and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes- Oxley
Act, and the applicable regulations thereunder that are designed to ensure that information required to be disclosed by the Company in
the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission’s rules and forms, including, without limitation, controls and procedures designed to ensure that information
required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated
to the Company’s management, including its principal executive officer and principal financial officer, or persons performing similar
functions, as appropriate to allow timely decisions regarding required disclosure and to ensure that material information relating to
the Company or the subsidiaries is made known to them by others within those entities, particularly during the period in which such periodic
reports are being prepared.

 

    	22

     

    

 

(t)
Secretary’s Certificate; Further Documentation. On or prior to the date of the first Placement Notice, the Company shall
deliver to the Agents a certificate of the Secretary of the Company and attested to by an executive officer of the Company, dated as
of such date, certifying as to (i) the Amended and Restated Certificate of Incorporation of the Company, (ii) the Amended and Restated
Bylaws of the Company, (iii) the resolutions of the Board of Directors of the Company authorizing the execution, delivery and performance
of this Agreement and the issuance of the Placement Shares and (iv) the incumbency of the officers duly authorized to execute this Agreement
and the other documents contemplated by this Agreement. Within five (5) Trading Days of each Representation Date, the Company shall have
furnished to the Agents such further information, certificates and documents as the Agents may reasonably request.

 

8.
Payment of Expenses. The Company will pay all expenses incident to the performance of its obligations under this Agreement, whether
or not the transactions contemplated hereby are consummated, including without limitation: (a) the preparation and filing of the Registration
Statement, including any fees required by the Commission, and the printing or electronic delivery of the Prospectus as originally filed
and of each amendment and supplement thereto, in such number as the Agents shall deem necessary, (b) the printing and delivery to the
Agents of this Agreement and such other documents as may be required in connection with the offering, purchase, sale, issuance or delivery
of the Placement Shares, (c) the preparation, issuance and delivery of the certificates, if any, for the Placement Shares to the Agents,
including any stock or other transfer taxes and any stamp duties or other similar duties or taxes payable upon the sale, issuance or
delivery of the Placement Shares to the Agents, (d) the fees and disbursements of the counsel, accountants and other advisors to the
Company, (e) the fees and expenses of the Agents including but not limited to the fees and expenses of the counsel to the Agents, in
an amount not to exceed (A) $100,000 payable upon the execution of this Agreement and (B) $15,000 in connection with each Representation
Date on which the Company is required to provide a certificate under Section 7(l), (f) the qualification or exemption of the Placement
Shares under state securities laws in accordance with the provisions of Section 7(r) hereof, including filing fees, but excluding
fees of the Agents’ counsel, (g) the printing and delivery to the Agents of copies of any Permitted Free Writing Prospectus (as
defined below) and the Prospectus and any amendments or supplements thereto in such number as the Agents shall deem necessary, (h) the
preparation, printing and delivery to the Agents of copies of the blue sky survey, (i) the fees and expenses of the transfer agent and
registrar for the Common Stock, (j) the filing and other fees incident to any review by FINRA of the terms of the sale of the Placement
Shares including the fees of the Agents’ counsel (subject to the cap, set forth in clause (e) above), and (k) the fees and expenses
incurred in connection with the listing of the Placement Shares on the Exchange.

 

9.
Conditions to the Agent’s Obligations. The obligations of the Agents hereunder with respect to a Placement will be subject
to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance
by the Company of its obligations hereunder, to the completion by the Agents of a due diligence review satisfactory to it in its reasonable
judgment, and to the continuing satisfaction (or waiver by the Agents in their sole discretion) of the following additional conditions:

 

(a)
Registration Statement Effective. The Registration Statement shall have become effective and shall be available for the (i) resale
of all Placement Shares issued to any Agent and not yet sold by the applicable Agent and (ii) sale of all Placement Shares contemplated
to be issued by any Placement Notice.

 

    	23

     

    

 

(b)
No Material Notices. None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request
for additional information from the Commission or any other federal or state Governmental Authority during the period of effectiveness
of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement
or the Prospectus; (ii) the issuance by the Commission or any other federal or state Governmental Authority of any stop order suspending
the effectiveness of the Registration Statement or the initiation or threat of any proceedings for that purpose or pursuant to Section
8A under the Securities Act; (iii) receipt by the Company of any notification from the Commission or any other federal or state Governmental
Authority with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale
in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that makes
any material statement made in the Registration Statement or the Prospectus or any material document incorporated or deemed to be incorporated
therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, the Prospectus
or such documents so that, in the case of the Registration Statement, it will not contain an untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make the statements therein not misleading and so that, in the
case of the Prospectus, it will not contain an untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

(c)
No Misstatement or Material Omission. An Agent or the Agents shall not have advised the Company that the Registration Statement
or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in any Agent’s reasonable opinion
is material, or omits to state a fact that in the Agent’s reasonable opinion is material and is required to be stated therein or
is necessary to make the statements therein not misleading.

 

(d)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission,
there shall not have been any material adverse change in the authorized capital stock of the Company or any Material Adverse Change or
any development that would reasonably be expected to cause a Material Adverse Change, or, if applicable, a downgrading in or withdrawal
of the rating assigned to any of the Company’s securities (other than asset backed securities) by any rating organization or a
public announcement by any rating organization that it has under surveillance or review its rating of any of the Company’s securities
(other than asset backed securities), the effect of which, in the case of any such action by a rating organization described above, in
the reasonable judgment of the Agents (without relieving the Company of any obligation or liability it may otherwise have), is so material
as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated
in the Prospectus.

 

(e)
Legal Opinions. The Agents shall have received the opinions and negative assurance letters of L&W, F&W and H&K required
to be delivered pursuant to Section 7(m) on or before the date on which such delivery of such opinions and negative assurance
letters is required pursuant to Section 7(m).

 

(f)
Comfort Letters. The Agents shall have received the Comfort Letters required to be delivered pursuant to Section 7(n) on
or before the date on which such delivery of such Comfort Letters is required pursuant to Section 7(n).

 

    	24

     

    

 

(g)
Representation Certificate. The Agents shall have received the certificate required to be delivered pursuant to Section 7(l)
on or before the date on which delivery of such certificate is required pursuant to Section 7(l).

 

(h)
No Suspension. Trading in the Common Stock shall not have been suspended on the Exchange and the Common Stock shall not have been
delisted from the Exchange.

 

(i)
Other Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 7(l), the Company
shall have furnished to the Agents such appropriate further information, certificates, letters and other documents as the Agents may
reasonably request. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof.

 

(j)
Securities Act Filings Made. All filings with the Commission required by Rule 424 under the Securities Act to have been filed
prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing
by Rule 424.

 

(k)
Approval for Listing. The Placement Shares shall either have been (i) approved for listing on the Exchange, subject only to notice
of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to,
the issuance of any Placement Notice.

 

(l)
FINRA. If applicable, FINRA shall have raised no objection to the terms of this offering and the amount of compensation allowable
or payable to the Agents as described in the Prospectus.

 

(m)
No Termination Event. There shall not have occurred any event that would permit the Agents to terminate this Agreement pursuant
to Section 12(a).

 

(n)
Actively Traded. The Common Stock shall be an “actively traded security” excepted from the requirements of Rule 101
of Regulation M under the Exchange Act by subsection (c)(1) of such rule.

 

10.
Indemnification and Contribution.

 

(a)
Company Indemnification. The Company agrees to indemnify and hold harmless the Agents, its affiliates and their respective partners,
members, directors, officers, employees and agents and each person, if any, who controls the applicable Agent or any affiliate within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:

 

(i)
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto),
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein
not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer
Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading;

 

(ii)
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate
amount paid in settlement of any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, in each
case, as described in Section 10(a)(i) above; provided that (subject to Section 10(d) below) any such settlement is effected
with the written consent of the Company, which consent shall not be unreasonably delayed or withheld; and

 

    	25

     

    

 

(iii)
against any and all reasonably incurred expenses whatsoever, as incurred (including the reasonably incurred fees and disbursements
of counsel), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding
by any Governmental Authority, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or
any such alleged untrue statement or omission (whether or not a party), in each case, as described in Section 10(a)(i) above,
to the extent that any such expense is not paid under (i) or (ii) above, provided, however, that this indemnity agreement shall
not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue
statement or omission made solely in reliance upon and in conformity with the Agent Information, provided, further, that this indemnity
agreement will be in addition to any liability that the Company may otherwise have.

 

(b)
Agent Indemnification. Each of the Agents agree, severally and not jointly, to indemnify and hold harmless the Company and its
directors and each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage
and expense described in the indemnity contained in Section 10(a), as incurred, but only with respect to untrue statements or
omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto), the Prospectus
(or any amendment or supplement thereto) or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) in reliance upon
and in conformity with information relating to the Agents and furnished to the Company in writing by the Agents expressly for use therein.
The Company hereby acknowledges that the only information that the Agents have furnished to the Company expressly for use in the Registration
Statement, the Prospectus or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) is the Agent Information.

 

(c)
Procedure. Any party that proposes to assert the right to be indemnified under this Section 10 will, promptly after receipt of
notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties
under this Section 10, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served,
but the failure to so notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it may have
to any indemnified party otherwise than under this Section 10 and (ii) any liability that it may have to any indemnified party under
the foregoing provision of this Section 10 unless, and only to the extent that, such omission results in the forfeiture of substantive
rights or defenses by the indemnifying party that results in damages to such indemnifying party. If any such action is brought against
any indemnified party and the indemnified party notifies the indemnifying party of such commencement, the indemnifying party, upon the
request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified
party and any others the indemnifying party may designate in such proceedings and shall pay the reasonably incurred fees and disbursements
of such counsel related to such proceedings. The indemnified party will have the right to employ its own counsel in any such action,
but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (A) the employment of
counsel by the indemnified party has been authorized in writing by the indemnifying party, (B) the indemnified party has reasonably concluded
(based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or
in addition to those available to the indemnifying party, (C) a conflict or potential conflict exists (based on advice of counsel to
the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the
right to direct the defense of such action on behalf of the indemnified party) or (D) the indemnifying party has not in fact employed
counsel to assume the defense of such action or counsel reasonably satisfactory to the indemnified party, in each case, within a reasonable
time after receiving notice of the commencement of the action, in each of which cases the reasonably incurred fees, disbursements
and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party
or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable
and documented fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any
one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying
party promptly as they are incurred. An indemnifying party will not, in any event, be liable for any settlement of or entry of any judgment
with respect to any action or claim effected without the indemnifying party’s written consent. No indemnifying party shall, without
the prior written consent of each indemnified party (which consent shall not be unreasonably conditioned, withheld or delayed), settle
or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters
contemplated by this Section 10 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent
(1) includes an express and unconditional release of each indemnified party from all liability arising out of such litigation, investigation,
proceeding or claim and (2) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf
of any indemnified party.

 

    	26

     

    

 

(d)
Settlement Without Consent if Failure to Reimburse. If an indemnified party shall have requested an indemnifying party to reimburse
the indemnified party for reasonable fees and expenses of counsel for which it is entitled to reimbursement under this Section 10, such
indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 10(a)(ii) effected
without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the
aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to
such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with
such request prior to the date of such settlement.

 

(e)
Contribution. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for
in the foregoing paragraphs of this Section 10 is applicable in accordance with its terms but for any reason is held to be unavailable
or insufficient from the Company or the Agents, the Company and the Agents will contribute to the total losses, claims, liabilities,
expenses and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid
in settlement of, any action, suit or proceeding or any claim asserted) to which the Company and the Agents may be subject in such proportion
as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Agents on the other hand. The
relative benefits received by the Company on the one hand and the Agents on the other hand shall be deemed to be in the same proportion
as the total net proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total
compensation received by the Agents from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided
by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate
to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one
hand, and the Agents, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense
or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative
fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact relates to information supplied by the Company or the Agents, the intent of the parties
and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and
the Agents agree that it would not be just and equitable if contributions pursuant to this Section 10(e) were to be determined by pro
rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein.
The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect
thereof, referred to above in this Section 10(e) shall be deemed to include, for the purpose of this Section 10(e), any legal or other
expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the
extent consistent with Section 10(c) hereof. Notwithstanding the foregoing provisions of this Section 10(e), no Agent shall be
required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation. For purposes of this Section 10(e), any person who controls a party to this Agreement
within the meaning of the Securities Act, any affiliates of the Agents and any officers, directors, partners, employees or agents of
the Agents or any of their affiliates, will have the same rights to contribution as that party, and each director of the Company and
each officer of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in
each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action
against such party in respect of which a claim for contribution may be made under this Section 10(e), will notify any such party or parties
from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may
be sought from any other obligation it or they may have under this Section 10(e) except to the extent that the failure to so notify such
other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement
entered into pursuant to the last sentence of Section 10(c) hereof, no party will be liable for contribution with respect to any
action or claim settled without its written consent if such consent is required pursuant to Section 10(c) hereof.

 

    	27

     

    

 

11.
Representations and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 10 of this
Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as
of their respective dates, regardless of (i) any investigation made by or on behalf of the Agents, any controlling persons, or the Company
(or any of their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement Shares
and payment therefor or (iii) any termination of this Agreement.

 

12.
Termination.

 

(a)
Each of the Agents shall have the right, by giving written notice to the Company and the other Agents, as hereinafter specified, to terminate
this Agreement in such Agent’s sole discretion at any time, with respect to such Agent only. Any such termination shall be without
liability of any party to any other party except that the provisions of Section 8 (Payment of Expenses), Section 10 (Indemnification
and Contribution), Section 11 (Representations and Agreements to Survive Delivery), Section 17 (Governing Law and Time;
Waiver of Jury Trial) and Section 18 (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such
termination. Following any termination by an Agent, the Agreement shall remain in effect as to each other Agent that has not exercised
its right to terminate the provisions of this Agreement pursuant to this Section 12(a) and any obligations and rights of the Agents under
this Agreement shall be satisfied by or afforded to, as applicable, only such other Agents that have not so terminated. If an Agent elects
to terminate this Agreement as provided in this Section 12(a), such Agent shall provide the required notice as specified in Section
13 (Notices).

 

(b)
The Company shall have the right, by giving notice to the Agents, as hereinafter specified, to terminate this Agreement in its sole discretion
at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except
that the provisions of Section 8, Section 10, Section 11, Section 17 and Section 18 hereof shall remain
in full force and effect notwithstanding such termination.

 

    	28

     

    

 

(c)
This Agreement shall remain in full force and effect unless terminated pursuant to Sections 12(a) and (b) above or otherwise
by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases be deemed
to provide that Section 8, Section 10, Section 11, Section 17 and Section 18 shall remain in full
force and effect.

 

(d)
Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that
such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company,
as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares
shall settle in accordance with the provisions of this Agreement.

 

13.
Notices. All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms
of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agents, shall be delivered to:

 

Evercore
Group L.L.C.

55
East 52nd Street

New
York, NY 10055

Attention:
ECM General Counsel

Facsimile:
(212) 857-3101

 

Citigroup
Global Markets Inc.

388
Greenwich Street

New
York, NY 10013

Attention:
General Counsel

Facsimile:
(646) 291-1469

 

Morgan
Stanley & Co. LLC

1585
Broadway

New
York, NY 10036

Attention:
Equity Syndicate Desk

Cc:
Legal Department

 

Needham
& Company, LLC

250
Park Avenue, 10th Floor

New
York, NY 10177

Attention:
Christopher Smajdor

Email:
csmajdor@needhamco.com

 

with
a copy to (which copy shall not constitute notice):

 

Fenwick
& West LLP

801
California Street

Mountain
View, CA 94041

Attention:
Ran Ben-Tzur & Michael S. Pilo

email:
rbentzur@fenwick.com & mpilo@fenwick.com

 

    	29

     

    

 

and
if to the Company, shall be delivered to:

 

fuboTV
Inc.

1290
Avenue of the Americas

New
York, NY 10104

Attention:
Gina Sheldon

email:
gsheldon@fubo.tv

 

with
a copy to (which copy shall not constitute notice):

 

Latham
& Watkins LLP

1271
Avenue of the Americas

New
York, NY 10020

Facsimile:
(212) 751-4864

Attention:
Greg Rodgers

Email:
greg.rodgers@lw.com

 

Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address
for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile
transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business
Day, on the next succeeding Business Day, (ii) by Electronic Notice as set forth in the next paragraph, (iii) on the next Business Day
after timely delivery to a nationally-recognized overnight courier or (iv) on the Business Day actually received if deposited in the
U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, “Business
Day” shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.

 

An
electronic communication (“Electronic Notice”) shall be deemed written notice for purposes of this Section
13 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received
at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic
Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”)
which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.

 

14.
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and the Agents and their respective
successors and the parties referred to in Section 10 hereof. References to any of the parties contained in this Agreement shall
be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights
or obligations under this Agreement without the prior written consent of the other party; provided, however, that each Agent may
assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company’s consent, so long as such affiliate
is a registered broker-dealer.

 

15.
Adjustments for Stock Splits. The parties acknowledge and agree that all share- related numbers contained in this Agreement shall
be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Placement Shares.

 

    	30

     

    

 

16.
Entire Agreement; Amendment; Severability; Waiver. This Agreement (including all schedules and exhibits attached hereto and Placement
Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof
may be amended except pursuant to a written instrument executed by the Company and each of the Agents. In the event that any one or more
of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written
by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it
is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal
or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder
of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver
by a party shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power,
or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any right, power, or privilege hereunder.

 

17.
Compliance with USA PATRIOT Act. In accordance with the requirements of the USA PATRIOT Act, each Agent is required to obtain,
verify and record information that identifies its clients, including the Company, which information may include the name and address
of its clients, as well as other information that will allow each Agent to properly identify its clients.

 

18.
Recognition of the U.S. Special Resolution Regimes.

 

(a)
In the event that an Agent is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from an Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same
extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation,
were governed by the laws of the United States or a state of the United States.

 

(b)
In the event that an Agent is a Covered Entity or a BHC Act Affiliate (as defined below) the Agent becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised against such Agent are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if
this Agreement were governed by the laws of the United States or a state of the United States.

 

For
purposes of this Section a “BHC Act Affiliate” has the meaning assigned to the term “affiliate”
in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k). “Covered Entity” means any of the
following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii)
a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b). “Default
Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81,
47.2 or 382.1, as applicable. “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance
Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and
the regulations promulgated thereunder.

 

19.
GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE
STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY
HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

    	31

     

    

 

20.
CONSENT TO JURISDICTION. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED
HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE
OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS
BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED)
TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND
SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS
IN ANY MANNER PERMITTED BY LAW.

 

21.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile
or by electronic delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN
Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com).

 

22.
Construction. The section and exhibit headings herein are for convenience only and shall not affect the construction hereof. References
herein to any law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority shall be deemed to refer
to such law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority as amended, reenacted, supplemented
or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated thereunder.

 

23.
Permitted Free Writing Prospectuses. The Company represents, warrants and agrees that, unless it obtains the prior written consent
of the Agents, and each Agent represents, warrants and agrees that, unless it obtains the prior written consent of the Company, it has
not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that
would otherwise constitute a “free writing prospectus,” as defined in Rule 405, required to be filed with the Commission.
Any such free writing prospectus consented to by the Agents or by the Company, as the case may be, is hereinafter referred to as a “Permitted
Free Writing Prospectus.” The Company represents and warrants that it has treated and agrees that it will treat each Permitted
Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433, and has complied and will comply
with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where
required, legending and record keeping. For the purposes of clarity, the parties hereto agree that all free writing prospectuses, if
any, listed in Exhibit 21 hereto are Permitted Free Writing Prospectuses.

 

24.
Absence of Fiduciary Relationship. The Company acknowledges and agrees that:

 

(a)
each Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between the Company
or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand,
and each Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement,
irrespective of whether or not such Agent has advised or is advising the Company on other matters, and no Agent has any obligation to
the Company with respect to the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;

 

    	32

     

    

 

(b)
none of the activities of an Agent or an affiliate of any Agent in connection with the transactions contemplated by this Agreement constitute
a recommendation, investment advice or solicitation of any action by such Agent or affiliate of such Agent with respect to any entity
or natural person;

 

(c)
it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;

 

(d)
no Agent or an affiliate of any Agent has provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated
by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;

 

(e)
it is aware that each Agent and its respective affiliates are engaged in a broad range of transactions which may involve interests that
differ from those of the Company and each Agent and its respective affiliates have no obligation to disclose such interests and transactions
to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and

 

(f)
it waives, to the fullest extent permitted by law, any claims it may have against any Agent or its respective affiliates for breach of
fiduciary duty or alleged breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that
each Agent and its respective affiliates shall not have any liability (whether direct or indirect, in contract, tort or otherwise) to
it in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on its behalf or in right of it or the
Company, employees or creditors of Company.

 

25.
Definitions. As used in this Agreement, the following terms have the respective meanings set forth below:

 

“Applicable
Time” means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement
and (iii) each Settlement Date.

 

“Governmental
Authority” means (i) any federal, provincial, state, local, municipal, national or international government or governmental
authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court,
tribunal, arbitrator or arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political subdivision
of any of the foregoing.

 

“Issuer
Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433, relating to the
Placement Shares that (1) is required to be filed with the Commission by the Company, (2) is a “road show” that is a “written
communication” within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt
from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not
reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act Regulations.

 

“Rule
164,” “Rule 172,” “Rule 405,” “Rule 415,”
“Rule 424,” “Rule 424(b),” “Rule 430B,” and “Rule
433” refer to such rules under the Securities Act Regulations.

 

All
references in this Agreement to financial statements and schedules and other information that is “contained,” “included”
or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to
mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration
Statement or the Prospectus, as the case may be.

 

All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall
be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing
Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission)
shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to “supplements”
to the Prospectus shall include, without limitation, any supplements, “wrappers” or similar materials prepared in connection
with any offering, sale or private placement of any Placement Shares by the Agents outside of the United States.

 

[Signature
Page Follows]

 

    	33

     

    

 

If
the foregoing correctly sets forth the understanding between the Company and the Agents, please so indicate in the space provided below
for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agents.

 

 

	 	Very
    truly yours,
	 	 
	 	FUBOTV
    INC.
	 	 	 
	 	By:
    	/s/ John Janedis
	 	Name:	John Janedis
	 	Title:	Chief Financial Officer
	 	 	 
	 	ACCEPTED
    as of the date first written above:
	 	 	 
	 	EVERCORE
    GROUP L.L.C.
	 	 	 
	 	By:
    	/s/ Sachin Aggarwal
	 	Name:	Sachin Aggarwal
	 	Title:	Senior Managing Director
	 	 	 
	 	CITIGROUP
    GLOBAL MARKETS INC.
	 	 	 
	 	By:
    	/s/ Derek Van Zandt
	 	Name:	Derek Van Zandt
	 	Title:	Managing Director
	 	 	 
	 	MORGAN
    STANLEY & CO. LLC
	 	 	 
	 	By:
    	/s/ Namrta Bhurjree
	 	Name:	Namrta Bhujree
	 	Title:	Vice President
	 	 	 
	 	NEEDHAM
    & COMPANY LLC
	 	 	 
	 	By:
    	/s/ Christopher Smajdor
	 	Name:	Christopher Smajdor
	 	Title:	Managing Director

 

[Signature
Page to the FuboTV Inc. Sales Agreement]

 

    	 

     

    

 

SCHEDULE
1

 

FORM
OF PLACEMENT NOTICE

 

	From:	fuboTV
    Inc.
	 	 
	To:	Evercore
    Group L.L.C.
	 	Citigroup
    Global Markets Inc. 
	 	Morgan
    Stanley & Co. LLC
	 	Needham
    & Company, LLC

 

	Attention:	[           ]
	 	 
	Subject:	Placement
    Notice
	 	 
	Date:	 

 

Ladies
and Gentlemen:

 

Pursuant
to the terms and subject to the conditions contained in the Sales Agreement by and among fuboTV Inc., a Florida corporation (the “Company”),
Evercore Group L.L.C., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Needham & Company, LLC dated August 4, 2022,
the Company hereby requests that [●], acting as the Designated Agent, sell up to [  ] of the Company’s common stock, par value
$0.0001 per share, at a minimum market price of $[   ] per share, during the time period beginning [month, day, time] and ending [month,
day, time].

 

	 	fuboTV
    Inc.
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 
	 	 	 
	 	cc:	[other
    fuboTV Inc. notice parties]

 

    	 

     

    

 

SCHEDULE
2

 

COMPENSATION

 

The
Company shall pay to the Designated Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount up to three
percent (3.00%) of the aggregate gross proceeds from each sale of Placement Shares.

 

    	 

     

    

 

SCHEDULE
3

 

NOTICE
PARTIES

 

The
Company

 

fuboTV
Inc.

 

David
Gandler, Chief Executive Officer

John
Janedis, Chief Financial Officer

Gina
Sheldon, General Counsel

 

The
Agents

 

Evercore
Group L.L.C.

 

Jay
Chandler, Senior Managing Director

Rob
Manning, Head of Trading

Sachin
Aggarwal, Managing Director

Doug
DePietro, Managing Director

Rob
Castello, Managing Director

Chris
Kolakowski, Associate

Ian
Edwards, Analyst

 

Citigroup
Global Markets Inc.

 

General
Counsel

 

Morgan
Stanley & Co. LLC

 

Equity Syndicate Desk

Legal Department

 

Needham
& Company, LLC

 

Christopher
Smajdor, Managing Director

Matthew
Castrovince, Principal

 

    	 

     

    

 

SCHEDULE
7(L)

 

FORM
OF REPRESENTATION DATE CERTIFICATE PURSUANT TO SECTION 7(L)

 

The
undersigned, the duly qualified and elected [   ], of fuboTV Inc., a Florida corporation (the “Company”), does
hereby certify in such capacity and on behalf of the Company, pursuant to Section 7(l) of the Sales Agreement, dated August 4, 2022
(the “Sales Agreement”), by and among the Company, Evercore Group L.L.C., Citigroup Global Markets Inc., Morgan
Stanley & Co. LLC and Needham & Company, LLC that to the best of the knowledge of the undersigned:

 

(i)
The representations and warranties of the Company in Section 6 of the Sales Agreement are true and correct on and as of the date hereof
with the same force and effect as if expressly made on and as of the date hereof, except for those representations and warranties that
speak solely as of a specific date and which were true and correct as of such date; provided, however, that such representations
and warranties also shall be qualified by the disclosure included or incorporated by reference in the Registration Statement and Prospectus;
and

 

(ii)
The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales
Agreement at or prior to the date hereof.

 

Capitalized
terms used herein without definition shall have the meanings given to such terms in the Sales Agreement.

 

	 	FUBOTV
    INC.
	 	 	      
	 	By:
    	 
	 	 	 
	 	Name:
    	 
	 	 	 
	 	Title:
    	 
	 	 	 
	 	Date:
    	 

 

    	 

     

    

 

EXHIBIT
21

 

PERMITTED
FREE WRITING PROSPECTUS

 

None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]